Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;49(9):106987.
doi: 10.1016/j.ejso.2023.106987. Epub 2023 Jul 13.

Molecular profiling of gastric neuroendocrine carcinomas

Ko Ikegame  1 , Keiichi Hatakeyama  2 , Masanori Terashima  3 , Takashi Sugino  4 , Daisuke Aizawa  4 , Kenichiro Furukawa  1 , Keiichi Fujiya  1 , Yutaka Tanizawa  1 , Etsuro Bando  1 , Ken Yamaguchi  5
Affiliations

Molecular profiling of gastric neuroendocrine carcinomas

Ko Ikegame et al. Eur J Surg Oncol. 2023 Sep.

Abstract

Gastric neuroendocrine carcinoma (G-NEC) usually has NEC and adenocarcinoma components and is considered to have a common origin in gastric adenocarcinoma because common pathogenic mutations are shared. However, G-NEC without adenocarcinoma also exists, and it may have a different mechanism of tumorigenesis. We aimed to elucidate the tumorigenesis of G-NEC by focusing on the proportion of NEC components. Thirteen patients with G-NEC were included in this study. Comprehensive genetic analysis using whole-exome sequencing was performed. G-NEC without an adenocarcinoma component was defined as pure NEC. TP53 was detected as the most frequent gene mutation (85% of the patients), independent of classification. RB1, KMT2C, LTBP1, and RYR2 mutations were identified in two of three pure NEC patients but were not detected in other G-NEC patients. Pure NEC has different somatic mutation profile than other NECs. This study provides insights into the mechanism of tumorigenesis in G-NEC.

Keywords: Gastric cancer; Molecular profiling; Neuroendocrine carcinoma; Pure NEC.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest MT reports receiving personal fees from Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, BMS, Yakult Honsha, Takeda Pharmaceutical, Eli Lilly Japan, Pfizer Japan, Daiichi Sankyo, Johnson and Johnson, Medtronic Japan, Intuitive Japan, and Olympus outside the submitted work. EB reports receiving personal fees from Johnson and Johnson, Medtronic Japan, Intuitive Japan, and Kaken Pharmaceutical outside the submitted work. The other authors declare no conflicts of interest.